Vorinostat [265,266,267,268,269], a HDAC inhibitor is used for the prevention of acute graft-versus-host disease, and the treatment of cutaneous T-cell lymphoma. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.